4.8 Review

Using Gene Editing Approaches to Fine-Tune the Immune System

Journal

FRONTIERS IN IMMUNOLOGY
Volume 11, Issue -, Pages -

Publisher

FRONTIERS MEDIA SA
DOI: 10.3389/fimmu.2020.570672

Keywords

immunotherapy; CARs; gene editing; graft-vs-host disease; base editors

Categories

Funding

  1. Spanish ISCIII Health Research Fund
  2. European Regional Development Fund (FEDER) [PI12/01097, PI15/02015, PI18/00337, PI18/00330]
  3. CECEyU and CSyF councils of the Junta de Andalucia FEDER/European Cohesion Fund (FSE) [2016000073391-TRA, 2016000073332-TRA, PI-57069, PAIDI-Bio326, PI-0014-2016]
  4. Nicolas Monardes regional Ministry of Health [0006/2018]
  5. Spanish Ministry of Science and Innovation (SMSI) [FPU16/05467, FPU17/02268]
  6. Industrial Doctorate Plan MCI [DIN2018-010180]
  7. SMSI [PEJ-2018-001760-A]
  8. LentiStem Biotech

Ask authors/readers for more resources

Genome editing technologies not only provide unprecedented opportunities to study basic cellular system functionality but also improve the outcomes of several clinical applications. In this review, we analyze various gene editing techniques used to fine-tune immune systems from a basic research and clinical perspective. We discuss recent advances in the development of programmable nucleases, such as zinc-finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), and clustered regularly interspaced short palindromic repeat (CRISPR)-Cas-associated nucleases. We also discuss the use of programmable nucleases and their derivative reagents such as base editing tools to engineer immune cells via gene disruption, insertion, and rewriting of T cells and other immune components, such natural killers (NKs) and hematopoietic stem and progenitor cells (HSPCs). In addition, with regard to chimeric antigen receptors (CARs), we describe how different gene editing tools enable healthy donor cells to be used in CAR T therapy instead of autologous cells without risking graft-versus-host disease or rejection, leading to reduced adoptive cell therapy costs and instant treatment availability for patients. We pay particular attention to the delivery of therapeutic transgenes, such as CARs, to endogenous loci which prevents collateral damage and increases therapeutic effectiveness. Finally, we review creative innovations, including immune system repurposing, that facilitate safe and efficient genome surgery within the framework of clinical cancer immunotherapies.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available